The objective of this prospective study was to assess the changes in anxiety levels, and their relationship with coping strategies over the first four months of fingolimod treatment in patients with relapsing remitting multiple sclerosis (RRMS). Data were collected at the inclusion visit (Visit 1) and 4 months later (Visit 2). We used the Hospital Anxiety and Depression Scale (HADS) to assess the level of anxiety and the Coping Inventory for Stressful Situations scale to assess the coping strategies used when engaged with stressful situations. The HADS anxiety scores were compared between Visits 1 and 2, according to the preferred coping strategy. At Visit 1, half of the 198 patients included were considered to be anxious (doubtful or in a certain way). The same proportion preferentially used an avoidance-oriented strategy and one-third preferentially used an emotion-oriented strategy. The mean HADS anxiety score decreased significantly (p = 0.001) at Visit 2 (8.1 ± 4.0) compared to Visit 1 (8.8 ± 4.3), particularly in the group of patients who used an emotion-oriented strategy (p = 0.002). In conclusion, the initiation of fingolimod in patients with RRMS is followed by a decrease of anxiety levels which vary according to the coping strategy used.

Keywords:
Multiple sclerosis, Anxiety, Coping, Fingolimod
1.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
2.
Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
3.
Confavreux C, Vukusic S, Achiti J: [Diagnostic criteria of different clinical forms]. Rev Neurol (Paris) 2001;157:907-913.
4.
Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, et al: Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012;7:e48078.
5.
Fromont A, Binquet C, Sauleau EA, Fournel I, Bellisario A, Adnet J, et al: Geographic variations of multiple sclerosis in France. Brain 2010;133(pt 7):1889-1899.
6.
Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al: A large-scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS register. PLoS One 2012;7:e41910.
7.
Rabinowitz AR, Arnett PA: A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. Neuropsychology 2009;23:581-591.
8.
Strober LB, Arnett PA: Unemployment among women with multiple sclerosis: the role of coping and perceived stress and support in the workplace. Psychol Health Med 2015, Epub ahead of print.
9.
Ukueberuwa DM, Arnett PA: Evaluating the role of coping style as a moderator of fatigue and risk for future cognitive impairment in multiple sclerosis. J Int Neuropsychol Soc 2014;20:751-755.
10.
Moreau T, Schmidt N, Joyeux O, Bungener C, Souvignet V: Coping strategy and anxiety evolution in multiple sclerosis patients initiating interferon-beta treatment. Eur Neurol 2009;62:79-85.
11.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria'. Ann Neurol 2005;58:840-846.
12.
Weiss DS, Marmar CR: The impact of event scale-revised; in Wilson JP, Keane TM (eds): Assessing Psychological Trauma and PTSD. New York, Guilford Press, 1997, pp 399-411.
13.
Brunet A, St-Hilaire A, Jehel L, King S: Validation of a French version of the impact of event scale-revised. Can J Psychiatry 2003;48:56-61.
14.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
15.
Guelfi J, et al: E. HADS Dépression et Syndromes Anxio-Dépressifs. Ardix Médical, 1999.
16.
Endler N, Parker JD: Assessment of multidimensional coping: task, emotion, and avoidance strategies. Psychol Assess 1994;6:50-60.
17.
Rolland J: CISS Inventaire de Coping Pour Situations Stressantes. Appliquée LEdCdP, 1998.
18.
Cosway R, Endler NS, Sadler AJ, Deary IJ: The coping inventory for stressful situations: factorial structure and associations with personality traits and psychological health. J Applied Biobehavioral Res 2000;5:121-143.
19.
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF: Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(suppl 1):S79-S83.
20.
Debouverie M, Pittion-Vouyovitch S, Guillemin F: [Reconsidering fatigue at the onset of multiple sclerosis]. Rev Neurol (Paris) 2009;165(suppl 4):S135-S144.
21.
Guy W: Clinical Global Impression: ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
22.
Kadouri A, Corruble E, Falissard B: The improved clinical global impression scale (iCGI): development and validation in depression. BMC Psychiatry 2007;7:7.
23.
McCabe MP, McKern S, McDonald E: Coping and psychological adjustment among people with multiple sclerosis. J Psychosom Res 2004;56:355-361.
24.
Zeidner M, Saklofske D: Adaptive and Maladaptive Coping. Handbook of Coping. New York, John Wiley & Sons, 1996, pp 505-531.
25.
Radat F, Mekies C, Géraud G, Valade D, Vivès E, Lucas C, et al: Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study. Cephalalgia 2008;28:1115-1125.
26.
Matuz T, Birbaumer N, Hautzinger M, Kübler A: Coping with amyotrophic lateral sclerosis: an integrative view. J Neurol Neurosurg Psychiatry 2010;81:893-898.
27.
Montel S, Bonnet AM, Bungener C: Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease. J Geriatr Psychiatry Neurol 2009;22:95-102.
28.
Danhauer SC, Crawford SL, Farmer DF, Avis NE: A longitudinal investigation of coping strategies and quality of life among younger women with breast cancer. J Behav Med 2009;32:371-379.
29.
Fournier M, de Ridder D, Bensing J: Optimism and adaptation to multiple sclerosis: what does optimism mean? J Behav Med 1999;22:303-326.
30.
Fournier M, De Ridder D, Bensing J: Optimism and adaptation to chronic disease: the role of optimism in relation to self-care options of type 1 diabetes mellitus, rheumatoid arthritis and multiple sclerosis. Br J Health Psychol 2002;7(part 4):409-432.
31.
Jean VM, Beatty WW, Paul RH, Mullins L: Coping with general and disease-related stressors by patients with multiple sclerosis: relationships to psychological distress. Mult Scler 1997;3:191-196.
32.
Montel SR, Bungener C: Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. Mult Scler 2007;13:393-401.
33.
Tan-Kristanto S, Kiropoulos LA: Resilience, self-efficacy, coping styles and depressive and anxiety symptoms in those newly diagnosed with multiple sclerosis. Psychol Health Med 2015;20:635-645.
34.
Goretti B, Portaccio E, Zipoli V, Razzolini L, Amato MP: Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 2010;31:S227-S230.
35.
Bakshi R: Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003;9:219-227.
36.
Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ: The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994;21:9-14.
37.
Ziemssen T: Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009;277(suppl 1):S37-S41.
38.
Tourbah A, Berger E, Debouverie M, De Seze J, Godet E, Moreau T: Efficacy and safety of fingolimod: the French grand-Est cohort. Neurology 2015;84:P3.249.
39.
Ziemssen T, Moser S, Fuchs A, Cornelissen C: Comparison of efficacy and treatment satisfaction of patients on baseline therapy or fingolimod: results of the interim analysis of two German registry studies PANGAEA and PEARL. Neurology 2014;82:P7.232.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.